NCT05625217Completed
Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer
Characterizing Dynamics of FDG Uptake With Total-Body PET for Response Assessment in Radiotherapy for Head and Neck Cancer
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
The overall goal of this research study is to understand how 18F-fluorodeoxyglucose (FDG), a radioactive sugar behaves in head and neck cancer (HNC) and inflammation immediately following injection and at many hours post-injection, with the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 7 (actual)
- First submitted
- 7 Nov 2022
- Start date
- 27 Feb 2023
- Primary completion date
- 20 Nov 2024
- Lead sponsor
- University of California, Davis
- Diseases
- Head and neck cancer
- NCT number
- NCT05625217
What you commit to
- Study type: Interventional
- Participants enrolled: 7
- From 27 Feb 2023 to the primary completion date, 20 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior RT for any malignancy leading to overlap with planned RT fields.
- Prior chemotherapy for any malignancy.
- Subjects who have had a research study involving radiation within one year of enrolling in this study
- Subjects who are pregnant (subjects 18 to 60 years old who are able to become pregnant unless documented hysterectomy or bilateral ovarian removal is available will be tested prior to injection of imaging agent - positive test will exclude from participating in the study)
Other illness
- Any significant medical condition that in the opinion of the investigator would prevent the subject from participating and/or adhering to study related procedures or interfere with subject safety (e.g., poorly controlled diabetes).
Age
- Children (\<18 years of age).
Other
- Subjects suffering from severe claustrophobia.
- Subjects who are breastfeeding
- Prisoners.
- Body weight more than 240 kg (529 pounds)
- \-
Who the study is looking for
- Stage II-IVa (American Joint Committee on Cancer, 8th edition) OC who are planned for RT (≥60 Gy) as per routine clinical standard.
- Patient must be ≥18 years of age.
- Willing and able to lay motionless in a supine position for up to 60 minutes
- Patient must be able to provide study specific informed consent prior to study entry.
- Patient must be able to adhere to the study visit schedule and other protocol requirements (including prolonged fasting).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UC Davis EXPLORER Molecular Imaging Center Coordinator of this site? Confirm its status | Sacramento | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.